Arvinas

Arvinas Focuses on Oncology and Neurodegenerative DiseasesArvinas is dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases by discovering, developing, and commercializing therapies that reduce pathogenic proteins. The company utilizes its proprietary technology platform to design proteolysis-targeting chimeras, or PROTACs, which are intended to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins.